Colorectal cancer is the third most common human cancer and the second most important cause of cancer-related death in Western countries, affecting men and women about equally. The etiology of sporadic colorectal cancer is relatively poorly understood, although diet is thought to play an important role in modifying risk. Vegetables, fruit, and dietary fiber are protective, whereas red and processed meats, fat, total energy intake, and obesity all increase risk ([@b34-ehp0112-001460]).

Diet is also an important source of exposure to many synthetic organic chemicals used in industry, agriculture, or accidentally released to the environment. Among them, the industrial organochlorine compounds (OCs) hexachlorobenzene (HCB) and polychlorinated biphenyls (PCBs) and the pesticides DDT (dichlorodiphenyltrichloroethane) and lindane \[γ-hexachlorocyclohexane (HCH), including α-HCH and β-HCH isomers\] have been classified as "probably" or "possibly" carcinogenic to humans \[[@b23-ehp0112-001460], [@b24-ehp0112-001460]\]. Most of the data for these classifications come from animal studies, although evidence for carcinogenic effects in humans is accumulating from occupational and nonoccupational exposure studies \[[@b5-ehp0112-001460], [@b6-ehp0112-001460]\].

Despite reductions in their use and fugitive release, OCs remain one of the most important groups of persistent pollutants to which humans are exposed, primarily via dietary intake. More lipophilic OCs, and those that are not easily metabolized, accumulate in adipose tissue, and the half-lives of these compounds in the body can be on the order of years or decades, whereas those compounds that are more water soluble or more easily metabolized have half-lives on the order of hours or days. Eventually, OCs recirculate in blood and are excreted in feces ([@b31-ehp0112-001460]). Serum concentrations are strongly correlated with fecal concentrations, particularly for the more lipophilic compounds that accumulate in adipose tissue and are generally more chlorinated ([@b25-ehp0112-001460]; [@b31-ehp0112-001460]). Exposure of tissue in the gastrointestinal tract to OCs is the result, therefore, not only of uptake from food but also of depuration from the tissue to the lumen. The long residence time (1--2 days) of feces in the colon offers potentially greater opportunity for exchange of OCs between the lumen and the epithelium than elsewhere in the gastrointestinal tract. However, the physicochemical characteristics of the compound (specifically, its solubility in water) will be more important in determining the relative importance of these exchange processes in the colon than in the small intestine, given the predominantly aqueous nature of the colonic milieu ([@b31-ehp0112-001460]; [@b38-ehp0112-001460]). Therefore, colon epithelium is likely to be a major target for putative carcinogenic effects of OCs via luminal and blood-borne exposure.

OCs have been shown to mimic hormones, and this has been postulated as a mechanism for carcinogenesis in hormone-dependent cancers ([@b14-ehp0112-001460]). Although colorectal cancer cannot be considered a hormone-dependent cancer, there is evidence that hormones play a role, at least in women: hormone replacement therapy and, possibly, high parity and oral contraceptive use are all protective factors ([@b35-ehp0112-001460]). Studies of cancers of the pancreas and breast have shown that OCs may interact with genetic alterations in tumors such as K-*ras* mutations or p53 overexpression ([@b22-ehp0112-001460]; [@b33-ehp0112-001460]; [@b40-ehp0112-001460]). Research on these interactions is relevant because they are frequent in colorectal cancer, and one potential mechanism of OC toxicity may be the induction of mutations in these genes.

Despite this, few studies of OC exposure and colorectal cancer risk have been published. Some studies in occupationally exposed cohorts have shown mixed results ([@b1-ehp0112-001460]; [@b7-ehp0112-001460]; [@b9-ehp0112-001460]; [@b12-ehp0112-001460]; [@b27-ehp0112-001460]; [@b45-ehp0112-001460]), whereas studies with data on individual plasma levels are rare. One study of colorectal cancer in children from rural areas exposed to pesticides showed no differences in serum OC levels compared with controls ([@b10-ehp0112-001460]). Higher (nonsignificant) serum concentrations of DDT and β-HCH in cases than in controls were reported in a small study of farmers in Egypt ([@b41-ehp0112-001460]).

To test the hypothesis that exposure to OCs plays an etiologic role in colorectal cancer, we determined serum concentrations in a subset of samples from a hospital-based case--control study. In addition, we investigated the relationship between OC concentrations and mutations of the K-*ras* and *p53* genes.

Materials and Methods
=====================

Study population.
-----------------

We conducted a hospital-based case--control study to assess gene--environment interactions in relation to colorectal cancer risk. A detailed description of the population and study methods has already been published ([@b26-ehp0112-001460]). Cases were patients with a new diagnosis of colorectal adenocarcinoma attending a university hospital in Barcelona, Catalonia, Spain, between January 1996 and December 1998. Controls were selected from admissions to the same hospital during this period using age and sex as frequency-matching criteria. To avoid selection bias of controls, the reason for admission had to be a disease not previously diagnosed for that patient. This criterion was used to avoid inclusion of patients with chronic diseases who might be repeatedly admitted to hospital and modify their habits because of their disease. This procedure paralleled the criterion for cases, who were also newly diagnosed incident cases. Main diagnosis groups of controls were acute digestive surgery (19%), urology (17%), gastroenterology (16%), and orthopedic surgery (15%). The study protocol was cleared by the ethics committee of the hospital, and all individuals gave written, informed consent to participate and for genetic analysis of their samples to be performed.

Of 523 identified cases, there were 13 (2%) refusals and 74 (14%) exclusions, with reasons including mental or other impairment and death or discharge before recruitment. We identified a total of 488 controls, with 36 (7%) refusals and 22 (5%) exclusions (reasons as described above). From these 436 cases and 430 controls, we selected a random sample of 140 cases and 80 controls for OC analyses for budgetary reasons. The sample size and imbalance in number between cases and controls was chosen to retain statistical power for our study of K-*ras* and *p53* mutations among cases \[80% power to detect odds ratios (ORs) of 2.25 for the exposures of interest\]. Controls for this study were selected using strata based on age, sex, and energy intake, the latter being used as a frequency-matching criterion because diet is a main source of exposure to OCs. Twelve samples were lost or excluded because of bad quality during laboratory analyses, and statistical tests were conducted on 132 cases and 76 controls.

Interviews.
-----------

Cases and controls were interviewed by trained personnel using a structured questionnaire. A dietary history questionnaire, previously developed and validated in the framework of the EPIC study \[European Prospective Investigation into Cancer and Nutrition (EPIC) Group of Spain 1997\], focused on average food consumption 1 year before diagnosis. Food groups based on bromatologic properties were calculated from reports of items consumed. Other risk factors measured were body mass index (BMI) at diagnosis and 10 years before, parity in women, and life-long history of nonsteroidal anti-inflammatory drugs (NSAIDs), tobacco, and alcohol use.

Organochlorine analysis.
------------------------

Selection of OCs for analysis was based on a literature search of commonly studied contaminants and included representatives of industrial and agrochemical compounds. Among the large family of PCB congeners, those often referred to as the ICES 7 (from International Council for the Exploration of the Sea), were selected: mono-*ortho* PCB congeners 28 and 118 and di-*ortho* PCBs 52, 101, 138, 153, 180. These PCB congeners are frequently found at high concentrations in humans and wildlife.

Nonfasting blood samples were obtained at diagnosis, and serum was isolated and analyzed "blind" for OCs. We calculated lipid-corrected concentrations of OCs by dividing serum OC concentrations by total plasma lipid concentrations estimated using the formula of [@b32-ehp0112-001460], and data are expressed in nanograms of OC per gram of lipid.

OCs were analyzed by gas chromatography after serum samples were subjected to liquid--liquid extraction and cleanup using concentrated sulfuric acid and hexane ([@b33-ehp0112-001460]). A mass spectrometer in negative chemical ionization mode was used to quantify α-, β-, γ-, and δ-HCH isomers; pentachlorobenzene (Pe-CB), HCB, PCB congeners, *p*,*p*′-DDT, and *p*,*p*′-DDE (4,4′-dichlorodiphenyltrichloroethene) were quantified on a gas chromatograph with electron capture detection. On both instruments, quantification was performed by external standards using PCB-142 as an injection standard to correct for volume. This method performed satisfactorily in an international intercalibration exercise within the Arctic Monitoring and Assessment Programme ([@b3-ehp0112-001460]).

Point mutations in K-ras and p53 genes, and expression of p53 protein.
----------------------------------------------------------------------

Fresh tumor tissue and normal mucosa samples were obtained from surgically extracted specimens of cases. K-*ras* gene mutations in codons 12 and 13 were detected and characterized by polymerase chain reaction (PCR) followed by single-strand conformation polymorphism (SSCP) analysis ([@b42-ehp0112-001460]). Aspartic acid mutations at codons 12 and 13 were confirmed by means of artificially introduced restriction fragment length polymorphism. Similarly, *p53* exons 4--9 were analyzed by PCR and SSCP followed by direct sequencing whenever necessary. Expression of the p53 protein was determined by immunohistochemistry, using commercially available antibodies (ab-6 Pantropic; Oncogene Research Products, VWR International GmBH, Darmstadt, Germany). We studied microsatellite instability by analyzing five microsatellite sequences ([@b18-ehp0112-001460]).

Statistical analysis.
---------------------

OC concentrations were categorized using tertiles based on all subjects. Some compounds were not detected in a high proportion of individuals. For these, the reference category consisted of values below the detection limit (LOD). When the proportion of individuals with detectable values was \> 50%, the values were further divided into two groups using the median value of those with values \> LOD.

Logistic regression was used to test the association between OCs and colorectal cancer. When cases were subdivided into groups according to genetic alterations, we used polytomous logistic regression, comparing each group of cases with the whole set of controls. All analyses were adjusted for age, sex, total energy intake, and BMI at diagnosis because these had been used as frequency-matching criteria or, in case of BMI, because of concerns about potential confounding of OC exposure by BMI, given that cases showing lower BMI might have undergone lipid-stored OC mobilization. The impact of these adjustments on risk estimates was minimal, however. We also excluded an association between OCs and tumor stage that would be indicative of bias, because more advanced tumors are associated with greater weight loss. Potential confounding by other variables associated with disease (alcohol, NSAIDs, and food groups) was explored and rejected. These were not included in the models to avoid losing efficiency in the estimates owing to excessive stratification.

ORs and 95% confidence intervals (CIs) were calculated for each group compared with the reference category. We tested for linear trend using the categorized variable as quantitative after assigning codes 1 to 3 to each category defined by tertiles. Interactions between exposures and genetic alterations in tumors were tested with logistic regression models comparing cases with the alteration to cases without it. All *p*-values calculated were two sided.

Results
=======

Characteristics of cases and controls are shown in [Table 1](#t1-ehp0112-001460){ref-type="table"}. Sex, age, and energy intake were used as frequency-matching criteria. BMI estimated 10 years before diagnosis was not related to disease. In contrast, BMI at diagnosis was inversely related to disease, probably due to cancer-related weight loss, although no association was found between plasma lipids and disease, or between plasma lipids and OC concentrations. In this population, alcohol intake, but not smoking, was a strong risk factor for colorectal cancer, both in duration and in average daily consumption. NSAIDs other than aspirin were protective but not significantly so.

OC levels.
----------

Lipid-corrected concentrations of OCs are shown in [Table 2](#t2-ehp0112-001460){ref-type="table"}. The most abundant compound was *p*,*p*′-DDE, followed by HCB and β-HCH. Summed PCB concentrations were similar to those of β-HCH. The proportions of samples with values lower than LODs are also shown in [Table 2](#t2-ehp0112-001460){ref-type="table"}. PCB-28 and PCB-52 were detected in only a small proportion of cases, although the LOD was very low. These compounds are more easily metabolized than are other PCBs because of the arrangement of their chlorine atoms and their lower degree of chlorination ([@b8-ehp0112-001460]). δ-HCH was not detected in any individual, and although Pe-CB and PCB-101 were detected in a few samples, their LODs were higher than other OCs; these three compounds were therefore excluded from statistical analyses.

Compounds were divided into two groups according to water solubility, and cases had slightly higher levels than did controls of both groups (data not shown). PCBs were grouped according to their structure, which is related to toxicity ([@b5-ehp0112-001460]; [@b37-ehp0112-001460]). Mono-*ortho* PCBs 28 and 118 have a relatively "planar" configuration compared with the remaining, di-*ortho* PCBs measured here. Exposure to mono-*ortho* PCBs 28 and 118 was almost double in cases compared with controls, whereas exposure to di-*ortho* PCBs was only slightly higher for cases than for controls.

OC levels and colorectal cancer risk.
-------------------------------------

[Table 3](#t3-ehp0112-001460){ref-type="table"} shows median lipid-corrected concentrations and 5th and 95th percentiles for each compound, separated for cases and controls. ORs for the association of OCs with colorectal cancer, adjusted for age, sex, BMI, and energy intake, are shown in [Table 4](#t4-ehp0112-001460){ref-type="table"}. Those significantly associated with an increased risk were mono-*ortho* PCBs 28 and 118, each with individual ORs \> 2 for the more exposed category. The OR for serum concentrations of the mono-*ortho* PCB group that combines PCB-28 and PCB-118 was 1.82 (95% CI, 0.90--3.70) in the middle tertile (LOD, 147 ng/g lipid) and 2.94 (95% CI, 1.39--6.20; *p*-value for trend = 0.004) for the highest tertile. Concentrations of di-*ortho* PCBs were not related to disease, nor was the classification of OCs according to their lipophilicity. High levels of α-HCH, HCB, and *p*,*p*′-DDE showed a nonsignificant increase in risk. Levels of *p*,*p*′-DDT were lower in cases than in controls in this population.

OC levels and interaction with other variables.
-----------------------------------------------

Dietary variables, which are both sources of exposure and risk factors for colorectal cancer, were explored as potential confounders. Specific food groups explored were vegetables, fruit, legumes, potatoes, meat, fish, eggs, dairy products, added fats, and pastries. Spearman's correlation coefficients between food groups and serum levels of specific OCs were in general low and nonsignificant (maximum *r* = 0.19). Exceptions worth mentioning were dairy products, which correlated with *p*,*p*′-DDT and PCB-101; fresh meats, which correlated with PCB-101, PCB-153, and PCB-180; and fish, which correlated with PCB-153 and PCB-180. The significance of these correlations was poor, and in addition to those correlations mentioned, we observed several negative correlations. We also used a multivariate logistic regression model with all food groups to generate a "dietary propensity factor," which could be interpreted as a score integrating the risk of colorectal cancer associated with diet. Adjusting OCs for this dietary propensity factor did not modify the risk estimates, showing again that diet was not a confounding factor. Hence, after careful consideration, adjustment of the analyses for food groups was found to be unnecessary because foods were not clearly related to serum OC levels and, more important, did not modify the risk estimates.

An exploratory analysis of interactions between mono-*ortho* PCBs and several variables was carried out. The magnitude of the risk of colorectal cancer observed for these OCs was not modified by sex, age, BMI, smoking, NSAIDs use, or parity in women. Analysis of interactions with other hormonal variables in women could not be performed because only six women were exposed to oral contraceptives and only two to postmenopausal hormone replacement treatments. Because alcohol was an important risk factor in this study and alcohol intake produces metabolic induction similar to that produced by some OCs ([@b30-ehp0112-001460]), interactions between OCs and alcohol were explored in detail, but none was significant.

OC levels and mutations at the K-ras and p53 genes.
---------------------------------------------------

K-*ras* was mutated in 50 (38%) cases. Most frequent mutations were GAT (*n* = 16) and GTT (*n* = 15) in codon 12. In 6 cases, codon 13 was mutated to GAC. Other, less frequent mutations in codon 12 were TGT (*n* = 5), AGT (*n* = 4), GCT (*n* = 3), and CGT (*n* = 1). Twenty-six mutations were transitions (G:C → A:T), and 24 were transversions (G:C → T:A).

Tumor suppressor gene *p53* was mutated in 59 (60%) of the tumors analyzed (data not available for 34 cases). Twenty-four mutations were located in hotspots: codon 175 (*n* = 4), codon 245 (*n* = 3), codon 248 (*n* = 3), codon 273 (*n* = 6), and codon 282 (*n* = 8). Four cases harbored mutations at codon 158, the remaining being detected at 24 different codons with frequencies ≤ 2. Forty mutations were transitions, and 15 were transversions; in the remaining four cases, deletions were detected. The most frequent base changes were C → T and G → A, each in 17 cases, mainly at hotspot sites. G → T changes were observed in eight cases and distributed with a nonclustered profile. The immunohistochemical analyses showed that 76% of the cases overexpressed the p53 protein.

[Table 5](#t5-ehp0112-001460){ref-type="table"} shows the analysis of selected OCs where the cases have been stratified by mutations in K-*ras* and *p53*. This analysis is based on polytomous logistic regression, and each group of cases is compared with controls in a unified model. Exposure to mono-*ortho* PCBs 28 and 118 increased risk in similar magnitude for both mutated and wild-type K-*ras*. PCB-118, but not PCB-28, showed higher risk for *p53*-mutated tumors, although the interaction was not significant. This stratification of cases by genetic alterations also showed some significant interactions with other OCs. High levels of *p*,*p*′-DDE were associated with increased risk of cancer with wild-type K-*ras*. Also, *p*,*p*′-DDE and α-HCH had significant effects on *p53*-mutated tumors. A similar pattern was evident when tumors were stratified according to p53 overexpression: *p*,*p*′-DDE and PCB-118 increased the risk only for tumors overexpressing p53 protein. Tumors with microsatellite instability were rare (*n* = 11, 8%), and these patients had similar OC levels to other cases.

Overall, 81% of the tumors harbored K-*ras* and/or *p53* gene mutations, and a combined analysis was performed. Exposure to high levels of the mono-*ortho* PCB-118 was associated with more mutations (OR = 2.89; 95% CI, 0.66--12.7), with transversions three times more likely than transitions ([Table 6](#t6-ehp0112-001460){ref-type="table"}). Other OCs analyzed in this way were not related to the type of mutation.

Discussion
==========

OCs have previously been associated with increased risk of colorectal cancers in studies of occupationally exposed individuals ([@b1-ehp0112-001460]; [@b41-ehp0112-001460]; [@b45-ehp0112-001460]). Other studies have failed to show this association ([@b19-ehp0112-001460]; [@b20-ehp0112-001460]; [@b39-ehp0112-001460]) or even have shown inverse associations with colon cancer ([@b12-ehp0112-001460]; [@b44-ehp0112-001460]). These mixed results are not surprising because most occupational studies lack individual exposure indicators and are prone to confounding. To overcome these limitations, we studied a population not occupationally exposed using serum OC levels as exposure markers. We found an elevated risk of colorectal cancer associated with high levels of mono-*ortho* PCBs 28 and 118. Other abundant OCs such as *p*,*p*′-DDE and α-HCH also showed an increased risk of relevant magnitude; although the associations for these OCs were not significant for the entire population of cases, they were significant for the subset of tumors harboring mutations of the *p53* gene.

We have taken serum concentrations of OCs as indicative of the body burden. Serum concentrations are strongly correlated with those in adipose tissue and feces and reflect the historical legacy of uptake and depuration, and as such, they may be taken as markers for long-term, low-level exposure ([@b2-ehp0112-001460]; [@b25-ehp0112-001460]; [@b31-ehp0112-001460]). Many studies that also used plasma OC concentrations as exposure markers have reported mixed results for breast cancer ([@b11-ehp0112-001460]) and non-Hodgkin lymphoma ([@b13-ehp0112-001460]; [@b16-ehp0112-001460]; [@b36-ehp0112-001460]) but increased risk of pancreatic cancer ([@b21-ehp0112-001460]; [@b33-ehp0112-001460]; [@b40-ehp0112-001460]). Altogether, these results suggest that a role for OCs in the etiology of several tumors is likely. Nevertheless, the mechanisms underlying carcinogenicity will differ among both OCs and target organs because chemical properties and toxicity mechanisms of these compounds are diverse. In addition, target organs differing in lipid content might determine distinct degree of local exposure.

In our population, high body burdens of mono-*ortho* PCBs 28 and 118 were associated with an elevated risk of colorectal cancer. These OCs are among the most toxic of the PCBs, together with non-*ortho* PCBs. The relatively flat (or "planar") orientation of their biphenyl rings allows them to bind to the aryl hydrocarbon (Ah) receptor in a similar way to polychlorinated dibenzodioxins and dibenzofurans and may be responsible for our finding ([@b37-ehp0112-001460]). This binding induces phase I and phase II metabolic enzymes; mono-*ortho* PCBs may therefore induce CYP1A and CYP2B enzymes that, in the absence of substrate, can produce reactive oxygen species. Although PCB-118 has a toxic equivalency factor (TEF) of 0.0001, based on its toxicity relative to 2,3,7,8-tetrachlorinated dibenzo-*p*-dioxin ([@b43-ehp0112-001460]), PCB-28 has not been assigned a TEF under this scheme and may not, therefore, bind strongly to the Ah receptor and/or significantly induce CYP enzymes. Nevertheless, higher serum levels of PCB-28 were associated with increased risk of colon cancer in this study. Some studies on breast cancer have also reported increased risk being limited to mono-*ortho* PCBs ([@b4-ehp0112-001460]; [@b15-ehp0112-001460]; [@b28-ehp0112-001460]).

PCBs themselves are hydroxylated by cytochrome P450 enzymes, and their metabolites have been shown to induce DNA adducts *in vitro* ([@b29-ehp0112-001460]). We have not observed a clear differential risk for PCB-28 or PCB-118 in relation to K *ras* or *p53* mutations. However, when mutations in both genes were classified according to their molecular nature, an association between transversions (less likely to occur spontaneously) and exposure to mono-*ortho* PCBs was observed. This could be interpreted as indirect evidence for a molecular fingerprint associated with exposure to these pollutants.

The role of other OCs in colorectal cancer risk may be more complex. Compounds such as *p*,*p*′-DDE and α-HCH that had an overall moderate association with colorectal cancer showed a significant increase in risk for tumors with mutation of the *p53* gene. A similar result was reported in a Danish study, where higher risk of breast cancer with mutated *p53* was observed among women exposed to high levels of dieldrin and PCBs ([@b22-ehp0112-001460]). In our population, *p*,*p*′-DDE also increased risk for tumors with wild-type K-*ras* but not when this oncogene was mutated. Previous studies in pancreatic cancer have provided mixed results regarding OC exposure and K-*ras* mutation status associated with DDE levels ([@b33-ehp0112-001460]; [@b40-ehp0112-001460]).

Several factors suggest that these findings may be causal: the strength and trend of the associations observed; the restriction of the findings to mono-*ortho* PCBs that have a relatively planar, dioxin-like structure; the existence of similar findings in tumors from other organs; the plausibility of carcinogenic mechanisms; and the association with specific mutation types. We are aware, however, that this study also has several limitations. Owing to the limitations of our analytical method, we did not study non-*ortho* PCBs that have a greater affinity for the Ah receptor than do mono-*ortho* PCBs as a result of their "coplanar" molecular structure, which may have strengthened our hypothesis. The retrospective assessment of exposure in the case--control design is not ideal, and the use of hospital controls may introduce information and selection bias. We minimized these biases by careful design, the use of validated questionnaires administered by trained interviewers, and robust analytical methods. However, potential sources of non-differential bias would tend to decrease the magnitude of any positive relationship; in particular, if OC exposure increased the risk of hospital admission, this would bias the associations toward the null hypothesis. Furthermore, potential confounding factors were explored in detail and rejected. Special effort was devoted to explore whether the weight loss observed among cases could explain the results, because OCs accumulate in lipids, and changes in BMI due to metabolism of adipose tissue in cancer patients could result in higher serum levels of OCs. However, three observations combine to negate this possibility: *a*) adjusting for BMI had only a minor effect on risk estimates; *b*) although more advanced cases exhibited severe weight loss, there was no association between OC levels and tumor stage; and *c*) if lipid mobilization was the reason for observing higher OC levels among cases, this would be true for all OCs but especially the more lipophilic compounds, whereas we observed increased risk only for selected OCs, and these were less lipophilic than *p*,*p*′-DDT and PCB-138, PCB-153, and PCB-180, for which no increased risk was observed. Nevertheless, we cannot exclude chance as an explanation of some of the results because this study was conceived as exploratory or hypothesis generating and we performed many statistical comparisons.

In conclusion, these results suggest that exposure to mono-*ortho* PCBs is associated with an increased risk of colorectal cancer. The trend and magnitude of the association and the specific toxic action of these PCBs, linked with transversion-type mutations, suggest that this finding may be causal. This hypothesis merits confirmation in other studies that would benefit from including other mono-*ortho* PCBs, as well as non-*ortho* PCBs and perhaps dioxins/furans.

###### 

Population characteristics.

                                                                                    Controls No. (%)   Cases No. (%)   OR (95% CI)         *p*-Value[*^a^*](#tfn1-ehp0112-001460){ref-type="table-fn"}
  --------------------------------------------------------------------------------- ------------------ --------------- ------------------- -------------------------------------------------------------
  Sex                                                                                                                                      
   Male                                                                             43 (57)            75 (57)         1.00                
   Female                                                                           33 (43)            57 (43)         1.07 (0.60--1.92)   
  Age (years)                                                                                                                              
   24--63                                                                           26 (34)            46 (35)         1.00                
   63--73                                                                           25 (33)            47 (36)         1.09 (0.54--2.20)   
   73--92                                                                           25 (33)            39 (30)         0.91 (0.45--1.83)   
  Energy intake (calories/day)                                                                                                             
   663--1,733                                                                       24 (32)            46 (35)         1.00                
   1,733--2,280                                                                     26 (34)            43 (33)         0.82 (0.39--1.73)   
   2,280--4,418                                                                     26 (34)            43 (33)         0.83 (0.38--1.82)   
  BMI                                                                                                                                      
   16.8--25.0                                                                       24 (32)            56 (42)         1.00                0.09
   25.0--30.0                                                                       33 (43)            51 (39)         0.65 (0.34--1.25)   
   30.0--40.7                                                                       19 (25)            25 (19)         0.53 (0.24--1.17)   
  BMI 10 years before diagnosis                                                                                                            
   17.6--25.0                                                                       19 (25)            42 (32)         1.00                0.79
   25.0--30.0                                                                       42 (55)            57 (43)         0.61 (0.31--1.20)   
   30.0--43.1                                                                       15 (20)            33 (25)         0.95 (0.41--2.18)   
  Plasma lipids (g/L)                                                                                                                      
   2.58--4.94                                                                       26 (34)            44 (33)         1.00                0.49
   4.94--5.85                                                                       21 (28)            48 (36)         1.37 (0.67--2.81)   
   5.85--9.55                                                                       29 (38)            40 (30)         0.79 (0.39--1.57)   
  Alcohol duration (years)                                                                                                                 
   0                                                                                34 (45)            42 (32)         1.00                0.05
   1--40                                                                            19 (25)            38 (29)         2.22 (0.93--5.30)   
   40--74                                                                           23 (30)            52 (39)         2.40 (1.02--5.63)   
  Alcohol consumption (g/day)                                                                                                              
   0                                                                                36 (47)            42 (31)         1.00                0.001
   1--60                                                                            35 (46)            66 (50)         2.42 (1.13--5.17)   
   60--410                                                                          5 (6)              24 (18)         7.39 (2.13--25.7)   
  Tobacco use (men[*^b^*](#tfn2-ehp0112-001460){ref-type="table-fn"})                                                                      
   Nonsmoker                                                                        9 (20)             20 (26)         1.00                0.47
   Ex-smoker                                                                        23 (53)            37 (49)         0.75 (0.29--2.00)   
   Smoker                                                                           11 (25)            18 (24)         0.66 (0.21--2.12)   
  Smoking duration (years, men[*^b^*](#tfn2-ehp0112-001460){ref-type="table-fn"})                                                          
   0                                                                                9 (21)             20 (27)         1.00                0.81
   1--40                                                                            20 (47)            22 (29)         0.48 (0.17--1.36)   
   40--79                                                                           14 (33)            33 (44)         1.05 (0.38--2.96)   
  Parity (women)                                                                                                                           
   0--2                                                                             6 (18)             16 (28)         1.00                0.78
   2--4                                                                             20 (61)            25 (44)         0.55 (0.17--1.76)   
   4--9                                                                             7 (21)             16 (28)         1.25 (0.31--5.11)   
  NSAID use                                                                                                                                
   None                                                                             52 (68)            101 (76)        1.00                0.12
   Aspirin                                                                          12 (15)            22 (16)         0.92 (0.42--2.04)   
   Other                                                                            12 (15)            9 (6)           0.43 (0.16--1.11)   

Test for linear trend adjusted for age, sex, energy intake, and BMI.

Only 6% of women ever smoked in this population.

###### 

Lipid-corrected serum concentrations of OCs.

  OC           Median[*^a^*](#tfn3-ehp0112-001460){ref-type="table-fn"} (cutpoints)[*^b^*](#tfn4-ehp0112-001460){ref-type="table-fn"}   LOD[*^c^*](#tfn5-ehp0112-001460){ref-type="table-fn"}   Percent of samples \> LOD[*^d^*](#tfn6-ehp0112-001460){ref-type="table-fn"}
  ------------ ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------- -----------------------------------------------------------------------------
  *p,p*′-DDE   3,686 (2,574--5,565)                                                                                                     0.2                                                     100
  *p,p*′-DDT   444 (336--740)                                                                                                           1.5                                                     100
  HCB          1,753 (1,344--2,522)                                                                                                     77.9                                                    98
  α-HCH        17 (\< 2.8--30)                                                                                                          2.8                                                     61
  β-HCH        1,057 (779--1,422)                                                                                                       34.4                                                    100
  γ-HCH        10 (\< 1.5--46)                                                                                                          1.5                                                     56
  PCB-28       \< 3.5 (\< 3.5)                                                                                                          3.5                                                     25
  PCB-118      92 (\< 21.0--127)                                                                                                        21.0                                                    62
  PCB-52       \< 4.6 (\< 4.6)                                                                                                          4.6                                                     9
  PCB-153      362 (255--487)                                                                                                           16.0                                                    100
  PCB-138      308 (245--404)                                                                                                           15.3                                                    98
  PCB-180      252 (190--333)                                                                                                           16.0                                                    98

Lipid-corrected concentrations expressed as ng/g lipid.

Cutpoints were 33rd and 66th percentiles, except for compounds for which the 33rd percentile was \< LOD, in which case median of measured values were used.

Lipid corrected (ng/g lipid) using average lipid concentration in the population (5.44 g lipid/L serum).

Proportion of samples with values \> LOD.

###### 

Lipid-corrected serum concentrations \[median (5th--95th percentile); ng/g lipid\] of OCs in cases and controls.

  OC           Cases                  Controls
  ------------ ---------------------- -------------------------
  *p,p*′-DDE   3,936 (600--11,804)    2,977 (611--13,608)
  *p,p*′-DDT   396 (124--2,077)       609 (137--3,848)
  HCB          1,753 (487--5,777)     1,763 (720--4,848)
  α-HCH        21 (\< 2.8--94)        14 (\< 2.8--55)
  β-HCH        1,042 (315--2,971)     1,119 (345--3,654)
  γ-HCH        10 (\< 1.5--121)       10 (\< 1.5--399)
  PCB-28       \< 3.5 (\< 3.5--228)   \< 3.5 (\< 3.5--43)
  PCB-118      103 (\< 21--319)       63 (\< 21--404)
  PCB-52       \< 4.6 (\< 4.6--49)    \< 4.6 (\< 4.6--\< 4.6)
  PCB-153      381 (118--1,018)       340 (118--917)
  PCB-138      327 (121--992)         301 (91--830)
  PCB-180      259 (87--741)          238 (72--650)

###### 

Risk of colorectal cancer associated with organochlorine body burden.

               Controls No. (%)   Cases No. (%)   OR (95% CI)         *p*-Value[*^a^*](#tfn7-ehp0112-001460){ref-type="table-fn"}
  ------------ ------------------ --------------- ------------------- -------------------------------------------------------------
  *p,p*′-DDE                                                          
   Low         31 (41)            38 (29)         1.00                0.19
   Medium      21 (28)            49 (37)         2.17 (1.03--4.54)   
   High        24 (32)            45 (34)         1.60 (0.79--3.25)   
  *p,p*′-DDT                                                          
   Low         25 (33)            44 (33)         1.00                0.12
   Medium      18 (24)            52 (39)         1.58 (0.74--3.36)   
   High        33 (43)            36 (27)         0.56 (0.27--1.17)   
  HCB                                                                 
   Low         29 (38)            40 (30)         1.00                0.23
   Medium      22 (29)            47 (36)         1.72 (0.83--3.54)   
   High        25 (33)            45 (34)         1.60 (0.62--4.15)   
  α-HCH                                                               
   Low         33 (43)            48 (36)         1.00                0.081
   Medium      27 (36)            37 (28)         0.99 (0.49--1.98)   
   High        16 (21)            47 (36)         2.02 (0.95--4.29)   
  β-HCH                                                               
   Low         26 (34)            44 (33)         1.00                0.81
   Medium      23 (30)            45 (34)         1.14 (0.55--2.36)   
   High        27 (36)            43 (33)         0.88 (0.39--2.02)   
  γ-HCH                                                               
   \< LOD      30 (39)            61 (46)         1.00                0.28
   Medium      22 (29)            36 (27)         0.79 (0.38--1.61)   
   High        24 (32)            35 (27)         0.69 (0.34--1.38)   
  PCB-28                                                              
   \< LOD      65 (86)            91 (69)         1.00                0.006
   \> LOD      11 (14)            41 (31)         2.75 (1.29--5.83)   
  PCB-118                                                             
   \< LOD      36 (47)            43 (33)         1.00                0.045
   Medium      20 (26)            39 (30)         1.63 (0.80--3.31)   
   High        20 (26)            50 (38)         2.02 (1.00--4.08)   
  PCB-52                                                              
   \< LOD      69 (91)            120 (91)        1.00                0.77
   \> LOD      7 (9)              12 (9)          1.16 (0.42--3.19)   
  PCB-153                                                             
   Low         30 (39)            39 (30)         1.00                0.57
   Medium      22 (29)            48 (36)         1.50 (0.74--3.07)   
   High        24 (32)            45 (34)         1.22 (0.59--2.52)   
  PCB-138                                                             
   Low         26 (34)            43 (33)         1.00                0.79
   Medium      26 (34)            44 (33)         0.85 (0.41--1.75)   
   High        24 (32)            45 (34)         0.90 (0.43--1.90)   
  PCB-180                                                             
   Low         29 (38)            41 (31)         1.00                0.63
   Medium      24 (32)            44 (33)         1.20 (0.59--2.42)   
   High        23 (30)            47 (36)         1.19 (0.57--2.49)   

*p*-Value for trend adjusted for age, sex, energy intake, and BMI.

###### 

Colorectal cancer risk for selected organochlorines in relation to K-*ras* and *p53* mutations.

                Wild-type   Mutated                                           
  ------------- ----------- ------------------- --------- ------------------- -------
  K-*ras*                                                                     
   *p,p*′-DDE                                                                 
    Low         16 (20)     1.00                22 (44)   1.00                0.012
    Medium      34 (41)     3.51 (1.49--8.24)   15 (30)   1.07 (0.42--2.72)   
    High        32 (39)     2.78 (1.21--6.35)   13 (26)   0.72 (0.29--1.81)   
   α-HCH                                                                      
    Low         28 (34)     1.00                20 (40)   1.00                0.55
    Medium      27 (33)     1.22 (0.57--2.61)   10 (20)   0.64 (0.25--1.66)   
    High        27 (33)     2.16 (0.94--4.97)   20 (40)   1.75 (0.70--4.37)   
   PCB-28                                                                     
    \< LOD      56 (68)     1.00                35 (70)   1.00                0.88
    \> LOD      26 (32)     2.78 (1.24--6.25)   15 (30)   2.83 (1.13--7.06)   
   PCB-118                                                                    
    \< LOD      26 (32)     1.00                17 (34)   1.00                0.42
    Medium      25 (30)     1.78 (0.81--3.90)   14 (28)   1.35 (0.53--3.43)   
    High        31 (38)     2.27 (1.04--4.96)   19 (38)   1.64 (0.67--4.01)   
  *p53*                                                                       
   *p,p*′-DDE                                                                 
    Low         12 (31)     1.00                11 (19)   1.00                0.047
    Medium      16 (41)     2.24 (0.81--6.16)   20 (34)   2.94 (1.11--7.76)   
    High        11 (28)     1.09 (0.39--3.05)   28 (47)   3.44 (1.39--8.47)   
   α-HCH                                                                      
    Low         18 (46)     1.00                16 (27)   1.00                0.045
    Medium      10 (26)     0.76 (0.29--2.01)   17 (29)   1.39 (0.58--3.35)   
    High        11 (28)     1.22 (0.44--3.34)   26 (44)   3.44 (1.40--8.45)   
   PCB-28                                                                     
    \< LOD      29 (74)     1.00                44 (75)   1.00                0.98
    \> LOD      10 (26)     2.16 (0.79--5.91)   15 (25)   2.06 (0.85--5.01)   
   PCB-118                                                                    
    \< LOD      14 (36)     1.00                18 (31)   1.00                0.19
    Medium      13 (33)     1.72 (0.65--4.53)   13 (22)   1.31 (0.53--3.26)   
    High        12 (31)     1.40 (0.52--3.75)   28 (47)   2.79 (1.22--6.37)   

*p*-Value for interaction between OC and the genetic alteration adjusted for age, sex, energy intake, and BMI; tests for differences in the OR between wild-type and mutated cases.

###### 

Colorectal cancer risk for PCB-118 in relation to K-*ras* and *p53* mutation type.

                                                                            Transitions[*^a^*](#tfn9-ehp0112-001460){ref-type="table-fn"}   Transversions[*^a^*](#tfn9-ehp0112-001460){ref-type="table-fn"}                                 
  ------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------------------- --------- ------------------- -------
  PCB-118                                                                                                                                                                                                                                   
   \< LOD                                                                   20 (37)                                                         1.00                                                              6 (18)    1.00                0.071
   Medium                                                                   17 (32)                                                         1.09 (0.28--4.28)                                                 12 (35)   3.29 (0.66--16.4)   
   High                                                                     17 (32)                                                         1.93 (0.41--9.09)                                                 16 (47)   6.52 (1.16--36.6)   
  Trend test *p*-value[*^c^*](#tfn11-ehp0112-001460){ref-type="table-fn"}   0.42                                                            0.038                                                                                           

Mutations in K-*ras* and *p53* classified as transitions (G:C→A:T) or transversions (G:C→T:A).

*p*-Value for interaction between PCB-118 and the mutation type; tests for differences in the OR between transitions and transversions.

Trend test *p*-value for the specific mutation type adjusted for age, sex, energy intake, and BMI.
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